Descazeaud A, Robert G, Delongchamps N B, Cornu J-N, Saussine C, Haillot O, Devonec M, Fourmarier M, Ballereau C, Lukacs B, Dumonceau O, Azzouzi A R, Faix A, Desgrandchamps F, de la Taille A
Service de chirurgie urologique, hôpital Dupuytren, CHU de Limoges, Limoges, France.
Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6.
To elaborate guidelines for the diagnosis, the follow-up, and the treatment of benign prostatic hyperplasia (BPH).
A systematic review of the literature was conducted to select more relevant publications. The level of evidence was evaluated. Graded recommendations were written by a working group, and then reviewed by a reviewer group according to the formalized consensus technique.
Terminology of the International Continence Society was used. Initial assessment has several aims: making sure that lower urinary tract symptoms (LUTS) are related to BPH, assessing bother related to LUTS and checking for a possible complicated bladder outlet obstruction (BOO). Initial assessment should include: medical history, LUTS assessment using a symptomatic score, physical examination including digital rectal examination, urinalysis, flow rate recording, and residual urine volume. Frequency volume chart is recommended when storage symptoms are predominant. Serum PSA should be done when the diagnosis of prostate cancer can modify the management. When a surgical treatment is discussed, serum PSA, serum creatinine and ultrasonography of the urinary tract are recommended. BPH patients should be informed of the benign and possibly progressive patterns of the disease. When LUTS cause no bother, annual follow-up should be planned. Medical treatment includes some phytotherapy agents, alpha-blockers and 5-alpha reductase inhibitors. The last two can be associated. The association of antimuscarinics and alpha-blockers can be offered to patients with residual storage symptoms when already under alpha-blockers therapy, after checking for the absence of severe BOO (residual volume more than 200mL or max urinary flow less than 10mL/s). Phosphodiesterase-5 inhibitors could be used in patients complaining for both LUTS and erectile dysfunction. In case of complication, or when medical treatment is inefficient or not tolerated, then a surgical treatment should be discussed. Treatment decision should be done according to type of LUTS and related bother, prostate anatomy, level of obstruction and its consequences on urinary tract, patient co-morbidities, experience of practitioner, and choice of patient. Surgical treatments with the higher level of evidence of efficacy include monopolar or bipolar transurethral resection of the prostate, open prostatectomy, transurethral incision of the prostate, photoselective vaporization of the prostate, and Holmium laser enuclation of the prostate.
Here are the first guidelines of the French Urological Association for the initial assessment, the follow-up and the treatment of urinary disorders related to BPH.
阐述良性前列腺增生(BPH)的诊断、随访及治疗指南。
对文献进行系统回顾以筛选更相关的出版物。评估证据水平。由一个工作组撰写分级推荐意见,然后由一个评审组根据形式化的共识技术进行评审。
采用国际尿控协会的术语。初始评估有多个目的:确保下尿路症状(LUTS)与BPH相关,评估与LUTS相关的困扰,并检查是否存在可能的复杂性膀胱出口梗阻(BOO)。初始评估应包括:病史、使用症状评分进行LUTS评估、体格检查(包括直肠指检)、尿液分析、尿流率记录及残余尿量。当储尿期症状为主时,建议使用频率 - 尿量图表。当前列腺癌的诊断可能改变治疗方案时,应检测血清PSA。讨论手术治疗时,建议检测血清PSA、血清肌酐及进行泌尿系统超声检查。应告知BPH患者该疾病的良性及可能进展的特点。当LUTS未造成困扰时,应计划每年进行随访。药物治疗包括一些植物治疗药物、α受体阻滞剂和5α还原酶抑制剂。后两者可联合使用。对于已接受α受体阻滞剂治疗且存在残余储尿期症状的患者,在检查排除严重BOO(残余尿量超过200mL或最大尿流率小于10mL/s)后,可给予抗毒蕈碱药物与α受体阻滞剂联合使用。磷酸二酯酶 - 5抑制剂可用于同时伴有LUTS和勃起功能障碍的患者。出现并发症、或药物治疗无效或无法耐受时,则应讨论手术治疗。治疗决策应根据LUTS的类型及相关困扰、前列腺解剖结构、梗阻程度及其对尿路的影响、患者合并症、医生经验及患者选择来做出。疗效证据水平较高的手术治疗包括单极或双极经尿道前列腺切除术、开放性前列腺切除术、经尿道前列腺切开术、选择性光汽化前列腺术及钬激光前列腺剜除术。
本文是法国泌尿外科学会关于与BPH相关的泌尿系统疾病的初始评估、随访及治疗的首批指南。